# reload+after+2024-01-21 21:46:58.207801
address1§4224 Campus Point Court
address2§Suite 210
city§San Diego
state§CA
zip§92121
country§United States
phone§858 202 6300
website§https://www.regulusrx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
fullTimeEmployees§29
companyOfficers§[{'maxAge': 1, 'name': 'Mr. Joseph P. Hagan M.B.A.', 'age': 54, 'title': 'CEO & Director', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 920728, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Crispina  Calsada CPA', 'age': 53, 'title': 'Chief Financial Officer', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 500866, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Christopher Ray Aker J.D.', 'age': 62, 'title': 'Senior VP, General Counsel & Corporate Secretary', 'yearBorn': 1961, 'fiscalYear': 2022, 'totalPay': 524790, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Preston S. Klassen M.D., M.H.S.', 'age': 54, 'title': 'President, Head of Research & Development and Director', 'yearBorn': 1969, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Daniel J. Penksa', 'age': 37, 'title': 'Executive Director of Finance & Controller', 'yearBorn': 1986, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Claire Susan Padgett M.S., M.T., Ph.D.', 'title': 'Senior Vice President of Clinical Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Rekha  Garg M.D., M.S.', 'title': 'Senior Vice President of Clinical Development & Regulatory', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.423
currency§USD
dateShortInterest§1702598400
forwardEps§-1.59
pegRatio§-0.02
exchange§NCM
quoteType§EQUITY
shortName§Regulus Therapeutics Inc.
longName§Regulus Therapeutics Inc.
firstTradeDateEpochUtc§1349789400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§cd43addf-be3b-3da4-8113-29f5cb221300
gmtOffSetMilliseconds§-18000000
targetHighPrice§12.0
targetLowPrice§2.0
targetMeanPrice§6.25
targetMedianPrice§5.5
recommendationMean§2.3
recommendationKey§buy
numberOfAnalystOpinions§4
quickRatio§3.732
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
